
Navigator's Role Along the Lung Cancer Patient Journey

As navigators caring for a patient diagnosed with lung cancer, you will find their journey may not be a straight path but instead, the journey for lung cancer patients involves...detours, periods where your patient may wait for new directions, even moments when your patients may have to back up and start again. Nurse and patient navigators working within the multidisciplinary team support patients with lung cancer and their families by offering key support along this path. The following roadmap describes the lung cancer patient journey.



Nurse & Patient Navigators, Sponsored by AstraZeneca.

Early Lung Cancer Detection and Intervention: Low-Dose Computed Tomography (LDCT) Lung Screening and Incidental Findings

- Conduct community outreach to at-risk patient populations¹
- Perform screening and culturally competent community outreach/education to healthcare providers via social media campaigns and advocacy groups²
- Offer education on new updated USPSTF criteria, what LDCT screening entails to encourage patients to get screened^{1,3-7}
- Create lung screening and incidental nodule management programs and protocols with emphasis on shared decision-making⁸

Diagnosis and Staging

START

- Perform labs, pulmonary function tests, imaging tests (ie, x-ray, CT, PET, or MRI)
- Determine tumor stage based on tumor size, lymph node involvement, and tumor metastasis¹³
- Perform biopsy to determine lung cancer type and subtype¹⁴⁻¹⁶
- Analysis of molecular driver mutations across all stages¹⁷
- Analysis of PD-L1¹⁷

STOP

- Utilize standard biomarker testing practices
- Introduce rationale for re-biopsy, if necessary, or obtaining liquid biopsy for future testing¹⁷

Navigators may expedite the staging activities, help patients understand the rationale for biomarker testing, coordinate biomarker testing, and maintain communication with all stakeholders.^{18,19}

BIOMARKER TESTING

US-62713 3/22

Page 1 of 2

During treatment planning, navigators help the patient evaluate their circumstances, assess potential barriers, and the impact treatment will have on the patient and their families.



Navigators' roles during treatment may include coordination of care, making referrals for supportive care, and providing educational and emotional support.

Navigators may conduct barrier assessment and distress screening to identify potential roadblocks to treatment adherence (such as financial issues, transportation, etc)²⁵⁻³⁰ and make early referral to local and national support services.

Survivorship and End of Life

Survivorship:

 Survivorship care planning, education on latent side effects, post-therapy rehabilitation^{19,31}

End of Life:

• Advance Care Planning discussion and completion, hospice^{18,32,33}

CT, computerized tomography **IPN**, incidental pulmonary nodule

References

MRI, magnetic resonance imaging PCP, primary care provider PD-L1, programmed death-ligand 1

ging PET, positron emission tomography USPSTF, US Preventive Services Task Force

Supportive Care²⁴

Nutrition/dietitian

Palliative care pre-surgery,

Financial Counselor/Social Worker

Psychologist/mental health consult

chemotherapy class, oral oncolytic
Pre-habilitation and oncology rehabilitation
Pulmonary rehabilitation/physical therapy
Advocacy/nonprofit group resources

Navigators coordinate survivorship

on the differences between palliative care

and hospice, and provide emotional support.

care plan development and offer guid-

ance on survivorship resources, educate

Krist AH, et al. JAMA. 2021;325:962-970. 2. Wang GX, et al. Radiology. 2019;290:278-287. 3. Moyer VA. Ann Intern Med. 2014;160:330-338. 4. Centers for Medicare & Medicaid Services. www.cms.gov/medicare-coverage-database/view/incacal-decision-memo.aspx?proposed=V&NCAId=274. Accessed March 23, 2022. 5. National Comprehensive Cancer Network®. www.nccn.org/professionals/physician_gls/pdf/lung_screening.pdf. Accessed March 23, 2022. 6. National Comprehensive Cancer Network®. www.nccn.org/professionals/physician_gls/pdf/lung_screening.pdf. Accessed March 23, 2022. 6. National Comprehensive Cancer Network®. www.nccn.org/professionals/physician_gls/pdf/lung_screening.pdf. Accessed March 23, 2022. 7. NatoMath 14, et al. Radiology. 2015;267:395-400. 12. MacMahon H, et al. Radiology. 2015;267:395-400. 12. MacMahon H, et al. Radiology. 2017;2842:28-243. 13. Sutic M, et al. J Pars Med. 2021;11:1102. 14. Travis WD, et al. J Thorac Oncol. 2015;10:1243-1260. 15. Bernardi FDC, et al. Clinics (Sav Paolo). 2018;73:861. 16. Lindeman NI, et al. J Thorac Oncol. 2015;823-859. 17. National Comprehensive Cancer Network®. www.nccn.org/professionals/physician_gls/pdf/inscl.pdf. Accessed March 23, 2022. 18. National Comprehensive Cancer Network®. www.nccn.org/professionals/physician_gls/pdf/inscl.pdf. Accessed March 23, 2022. 18. Unnihell LS. Lung Cancer Manage. 2014;3:229-231. 19. Deerfler-Evans RE. J Thorac Disc. 2016;8(Suppl 6):S498-S500. 20. Hardavella G, et al. Breathe (Sheff). 2020;16:200076. 21. Mazzone PJ, et al. Chest. 2021;16:0368-378. 22. Holden CE, et al. PLoS One. 2021;16:025395. 23. Mokhles S, et al. Interact Cardiovasc Thorac Surg. 2017;25:278-284. 24. 016:-Green S, et al. J Psychosc Oncol. 2013;29:27-75. 26. Fischer SM, et al. J Palliat Med. 2007;10:1203-128. 27. Shlay JG, et al. Prev Chronic Dis. 2011;8::432-431-446. 25. Freeman HP. Semin Oncol Nurs. 2013;29:72-75. 26. Fischer SM, et al. J Palliat Med. 2007;10:1203-7168. 27. Shlay JG, et al. Prev Chronic Dis. 2014;8::431-44. 28. Goff SL, et al. Trais. 2013;41

At the end of the patient's journey, navigators encourage the patient to follow up with their PCP regarding overall health and encourage patient compliance with oncology and surgical specialists' future recommendations.¹⁷

Throughout the recommended duration of therapy, navigators provide education and set expectations with the patient and caregivers about treatment side effects,²² continue to reinforce shared decision-making, and promote patient adherence to clinical protocols.²³

Side Effect Management and Adherence

Monitoring Dependent on Disease Stage

- Management of symptoms and treatment side effects through the end of treatment¹⁸
- Additional imaging to evaluate recurrence, progression, and/or treatment response¹⁷
- Repeat biopsy and biomarker testing in case of tumor progression or recurrence¹⁷

Navigators educate on long-term side effects from treatment and reinforce the importance of future screening and testing.

